MedPath

A prospective observational study to evaluate the detection rate of actionable mutations by liquid biopsy Guardant360 in patients with non-squamous non-small cell lung cancer (NSCLC) whose gene alterations are not detected by tissue-based singleplex assays. (WJOG13620L)

Not Applicable
Conditions
ung Cancer
Registration Number
JPRN-UMIN000041583
Lead Sponsor
West Japan Oncology Group
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
Complete: follow-up complete
Sex
All
Target Recruitment
72
Inclusion Criteria

Not provided

Exclusion Criteria

1) Multiple cancer with metastasis. 2) Severe psychological disease. 3) Not fit for this trial judged by the doctor in charge.

Study & Design

Study Type
Observational
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Secondary Outcome Measures
NameTimeMethod
© Copyright 2025. All Rights Reserved by MedPath